The NIBIB Director Dr. Bruce Tromberg discusses the latest accomplishment by the RADx Tech Independent Test Assessment Program with the authorization of the first point-of-care hepatitis C virus diagnostic test.
NIBIB Director Dr. Bruce Tromberg marks the two-year anniversary of RADx® Tech, and takes a brief look back at its formation, impact, and potential for future growth.
NIBIB is proud to be one of the co-sponsors of the exciting new NIH Common Fund initiative Bridge2AI which aims to dramatically advance widespread adoption of artificial intelligence (AI) as a tool for biomedical research.
A quiet healthcare revolution is taking place, driven by an urgent national need and fueled by cutting-edge technologies. Diagnostics have changed, and more COVID-19 tests are now performed in point of care (POC) and home settings than in central labs. NIBIB is now looking forward with the goal of leveraging this unprecedented transformation.
An innovative online tool funded by NIBIB helps organizations choose a COVID-19 testing strategy that will work best for their specific needs.
2021 is finally here and most of us are thrilled to put last year in the rear-view mirror. Although the rollercoaster month of January hasn’t been the smoothest of starts, there are many positive signs that a brighter future is just around the corner.
Several months ago in this space I wrote that bioengineered technologies for COVID-19 testing must ultimately be deployed to help reduce the spread of the virus and return us safely to full function as a society. Since then, through a massive response by the bioengineering community in support of the RADx initiative, we have awarded contracts worth $ 513.1 million to 25 small and large biomedical diagnostic companies for scale-up and manufacturing.
NIBIB's goal is to accelerate research, translation, and commercialization of technologies that will make a difference in the battle against COVID-19.
The Business and Innovation blog of PhysicsWorld.com featured a post about Bruce Tromberg’s plenary talk at the Photonics West conference in San Francisco.
A multi-institutional collaboration, led by the NIBIB will create new tools that physicians can use for early detection and personalized therapies for COVID-19 patients.